Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. More Details
Excellent balance sheet and overvalued.
Share Price & News
How has Cyclerion Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CYCN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: CYCN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: CYCN underperformed the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: CYCN underperformed the US Market which returned 39.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cyclerion Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StInsider Buying: The Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) CEO & Director Just Bought 67% More Shares
4 months ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?
5 months ago | Simply Wall StCan You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?
Is Cyclerion Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CYCN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CYCN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CYCN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CYCN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CYCN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CYCN is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (3.4x).
How is Cyclerion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cyclerion Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cyclerion Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CYCN is currently unprofitable.
Growing Profit Margin: CYCN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CYCN is unprofitable, but has reduced losses over the past 5 years at a rate of 0.7% per year.
Accelerating Growth: Unable to compare CYCN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYCN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: CYCN has a negative Return on Equity (-146.54%), as it is currently unprofitable.
How is Cyclerion Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CYCN's short term assets ($44.4M) exceed its short term liabilities ($13.5M).
Long Term Liabilities: CYCN's short term assets ($44.4M) exceed its long term liabilities ($38.1M).
Debt to Equity History and Analysis
Debt Level: CYCN's debt to equity ratio (7.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CYCN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYCN has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CYCN is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.
What is Cyclerion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CYCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CYCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CYCN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CYCN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CYCN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Hecht (56 yo)
Dr. Peter M. Hecht, Ph.D., served as the Chief Executive Officer of Ironwood Pharmaceuticals, Inc. since 1998 until April 1, 2019. Dr. Hecht is Chief Executive Officer and Director of Cyclerion Therapeutic...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD365.99K) is below average for companies of similar size in the US market ($USD528.84K).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
Experienced Management: CYCN's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Experienced Board: CYCN's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CYCN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.6%.
Cyclerion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cyclerion Therapeutics, Inc.
- Ticker: CYCN
- Exchange: NasdaqGS
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$150.366m
- Shares outstanding: 40.42m
- Website: https://www.cyclerion.com
Number of Employees
- Cyclerion Therapeutics, Inc.
- 301 Binney Street
- United States
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/19 15:53|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.